

phaematologica *the hematology journal*

author contribution form

Title	First line treatment with rituximab- Hyper-CVAD alternating with rituximab- Methotrexate- Cytarabine and followed by consolidation with ⁹⁰ Y- Ibritumomab-Tiuxetan in patients with mantle cell lymphoma. Results of a phase 2 pilot multicenter trial from the GELTAMO group
First author	Reyes Arranz

According to the International Committee of Medical Journal Editors (ICMJE)

(http://www.icmje.org/ethical_1author.html):

“Authorship credit should be based on: 1) substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; 2) drafting the article or revising it critically for important intellectual content; and 3) final approval of the version to be published. Authors should meet conditions 1, 2 and 3. Acquisition of funding, collection of data, or general supervision of the research group alone does not constitute authorship”.

The responsible author(s) of this manuscript confirm(s) that all persons designated as authors qualify for authorship, and that each author has participated sufficiently in the work to take public responsibility for appropriate portions of the content.

Specific contributions of each author are listed on page 2 of this document.

Responsible author(s):

author(s) responsible for the integrity of the work as a whole

Name: Reyes Arranz; MD, PhD
Institute: Hospital Universitario de la Princesa, Madrid, Spain
e-mail: rarranzs@telefonica.net

Name: Ana García – Noblejas MD
Institute: Hospital Universitario de la Princesa, Madrid, Spain
e-mail: agnoblejas@yahoo.com

Name: Dolores Caballero; MD, PhD
Institute: Hospital Universitario Clínico de Salamanca, Salamanca, Spain
e-mail: cabarri@usal.es

Author contributions (maximum 1 page):

Please describe the contributions of each author, indicating who was responsible for each part of the study and the preparation of the manuscript (collection of data, experiments, data analysis, generation of figures, collection of images, interpretation of data, preparation of the text, etc.)

Reyes Arranz coordinated the study, interpreted data analysis and wrote the manuscript. Ana García- Noblejas and Jimena Cannata- Ortiz helped to interpret the data and to the writing of the paper. Reyes Arranz, Ana García- Noblejas, Carlos Grande, M^a José Terol, Jose J. Sánchez, Concepción Aláez, Javier Pérez Calvo, Miguel A. Canales; José García- Marco, Eulogio Conde, Antonio Salar, and Dolores Caballero were responsible for patients clinical management. Jimena Cannata- Ortiz was involved in the acquisition data and statistical analysis. José García- Marco, Antonio Salar, Carlos Grande, Alejandro Martín and Dolores Caballero contributed to the interpretation of the data and to the revision of the manuscript. Eva Arranz performed the cytogenetic analysis. All the authors approved the final version to be submitted.